Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 V211D |
Therapy | Binimetinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 V211D | Advanced Solid Tumor | predicted - resistant | Binimetinib | Preclinical - Biochemical | Actionable | In a preclinical study, Mektovi (binimetinib) did not inhibit kinase activity of MAP2K1 V211D in an in vitro assay (PMID: 31227518). | 31227518 |
PubMed Id | Reference Title | Details |
---|---|---|
(31227518) | V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. | Full reference... |